Morgan Stanley Discount Zert ATO .../ DE000ME80CN3 /
2024-05-02 8:54:29 AM | Chg.+0.16 | Bid12:42:01 PM | Ask12:42:01 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.02EUR | +8.60% | 1.90 Bid Size: 50,000 |
2.04 Ask Size: 50,000 |
Atos SE | - EUR | 2024-06-28 | Call |
GlobeNewswire
04-29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
04-15
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire
04-11
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
GlobeNewswire
04-09
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...
GlobeNewswire
04-01
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire
03-25
Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks
GlobeNewswire
03-19
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...
GlobeNewswire
03-18
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
GlobeNewswire
03-12
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...
GlobeNewswire
03-06
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...
GlobeNewswire
02-22
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
GlobeNewswire
01-16
New report reveals that 94% of global organizations have experienced email security incidents last y...
GlobeNewswire
2023-12-04
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
GlobeNewswire
2023-11-20
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
GlobeNewswire
2023-11-13
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-11-09
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors